Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Non-Current Liabilities (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Total Non-Current Liabilities data on record, last reported at -$275.0 million in Q2 2025.

  • For Q2 2025, Total Non-Current Liabilities fell 354.6% year-over-year to -$275.0 million; the TTM value through Jun 2025 reached -$275.0 million, down 354.6%, while the annual FY2024 figure was $92.3 million, 17.97% down from the prior year.
  • Total Non-Current Liabilities reached -$275.0 million in Q2 2025 per ZNTL's latest filing, down from $92.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $112.5 million in Q4 2023 and bottomed at -$275.0 million in Q2 2025.
  • Average Total Non-Current Liabilities over 4 years is $61.6 million, with a median of $97.7 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 126.25% in 2023, then crashed 354.6% in 2025.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $102.7 million in 2022, then grew by 9.6% to $112.5 million in 2023, then decreased by 17.97% to $92.3 million in 2024, then plummeted by 397.93% to -$275.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were -$275.0 million in Q2 2025, $92.3 million in Q4 2024, and $108.0 million in Q2 2024.